Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus LAMIVUDINE ZIDOVUDINE ABACAVIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus LAMIVUDINE ZIDOVUDINE ABACAVIR.
EMTRICITABINE vs LAMIVUDINE; ZIDOVUDINE; ABACAVIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Lamivudine, zidovudine, and abacavir are nucleoside reverse transcriptase inhibitors (NRTIs). They are phosphorylated intracellularly to active metabolites that compete with natural nucleotides for incorporation into viral DNA, causing chain termination and inhibition of HIV reverse transcriptase.
200 mg orally once daily, typically in combination with other antiretroviral agents.
One tablet (300 mg abacavir, 150 mg lamivudine, 300 mg zidovudine) orally twice daily.
None Documented
None Documented
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Lamivudine: 5-7 hours (single dose), prolonged to ~11 hours in renal impairment; Zidovudine: 1.1 hours (terminal), increased to 1.4 hours in hepatic impairment; Abacavir: 1.5 hours (terminal), slightly prolonged in hepatic impairment; Clinical context: Dosing interval of 12 hours requires therapeutic drug monitoring in renal/hepatic dysfunction.
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Lamivudine: ~70% excreted unchanged in urine via glomerular filtration and active tubular secretion; Zidovudine: ~75% excreted as metabolites (primarily 5'-glucuronide) in urine, with <20% unchanged; Abacavir: ~83% excreted as metabolites in urine (via alcohol dehydrogenase and glucuronidation) and ~16% in feces; Total renal elimination accounts for >80% of clearance for all three components.
Category C
Category A/B
Antiretroviral, NRTI
NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."